about
Use of praziquantel as an adjuvant enhances protection and Tc-17 responses to killed H5N1 virus vaccine in miceSublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in miceIntranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protectionConserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine developmentNovel strategies for prevention and treatment of influenza.Pandemics, avian influenza A (H5N1), and a strategy for pharmacists.Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses.Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses.Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains."Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?".Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccineNovel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner.A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina)A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats.Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses.Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus.Molecular basis of live-attenuated influenza virus.In vivo assessment of NS1-truncated influenza virus with a novel SLSYSINWRH motif as a self-adjuvanting live attenuated vaccineA replication-incompetent PB2-knockout influenza A virus vaccine vector.The role of reverse genetics in the development of vaccines against respiratory viruses.A Bivalent Vaccine Based on a PB2-Knockout Influenza Virus Protects Mice From Secondary Pneumococcal Pneumonia.Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines.Immunogenetics of seasonal influenza vaccine responseEpitope specificity of anti-HA2 antibodies induced in humans during influenza infectionEssential role of the NV protein of Novirhabdovirus for pathogenicity in rainbow trout.Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protectionInduction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors.Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years.Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes.Detection of influenza A/H1N1-specific human IgG-secreting B cells in older adults by ELISPOT assay.Longitudinal analysis of genotype distribution of influenza A virus from 2003 to 2005.Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.
P2860
Q27304934-F703EB98-D68B-458F-8E96-48448751E77CQ28727930-12F8D771-79F9-4ED6-8359-A9DAC2A44135Q28744570-35A612AD-CA5D-4429-947D-FDB3B51AD097Q30226873-46ABF305-C1DF-4005-919F-025F8B10125CQ30350342-523566F2-9155-4176-90E4-A53E08FF1E71Q30353151-B8587E48-89B4-4C4D-88D9-961B63683968Q30362794-4A927B98-70DB-44CD-9FA0-F4D9A54C7759Q30369828-96A4CF03-871B-416B-AFE2-55DAB747C4D5Q30372521-CE265BE5-D9E9-410F-820F-30D7242E913EQ30373963-D5516A98-ED7E-4E48-8C97-3A3F3C02097CQ30375489-342ACC25-67BA-46CB-8323-86DEBF314642Q30402334-38D13502-809F-412E-A9B7-CA3B8D444248Q30421357-173E30CB-B78B-49EF-8640-1357277DAD1CQ30421413-8394F9D8-BDD3-4B84-8EFE-EBC901E0FE30Q30429134-D67A744C-9190-4B91-911E-37E30CB37F5AQ30430275-C42259F5-2006-42B4-931F-38285DED7E4BQ33206816-A65EB851-0BDC-429A-BABF-093384A20139Q33226128-0B5AD6C0-0539-4F6A-ADBC-5E6D73443FDEQ33226785-732B4A65-9E1E-4040-BE86-DC667D063D9DQ33843078-F72F64B9-22F3-418C-B9B8-3F641F1F4910Q33886927-31B982B2-5351-4AD8-B8B3-0D2E99E35BC6Q34555913-89634CD3-1099-4598-92DC-1926F266A3DEQ34653879-BB4DB441-8EA4-41FD-9DD7-00678560FB8CQ35581453-000B6174-B263-4E0E-BA83-66EC5E9BF3E6Q35868034-50BA82E9-6E5A-4CDB-8BDF-654608D33BC4Q36099468-86C2A3E9-30D6-48D0-8E2A-268B01C367B9Q36306944-777A37D4-C92C-42B4-9ECF-471E490B142CQ36898706-C48B5C86-0036-4D18-BB0F-2F74B1D30AF4Q36948581-5DFEFA10-8A72-47F6-96E3-26DEB4E17504Q37030332-40B6024E-A2A1-4E79-B8D3-C426424D29F4Q37087170-78196499-A4D6-4AEE-8112-F623745DCB69Q37093265-4F18916D-7163-43DA-96B0-5C166C12955CQ37212827-B9AC8E38-59EC-48A3-86E6-51ACE739384FQ37348513-452FE03F-FB90-4B67-A0D3-AD590E0FED88Q37530450-BFFD9780-4FC7-4174-8DE0-26414C53959CQ37596474-EE552BA4-6A3B-4107-990A-FDB937360173Q37629980-96D995C4-BD58-43F2-A658-5644CDB0B280Q38479480-3C885D17-CB07-4F00-BA37-D1E1BD4D138DQ39320513-37F74C96-1B0A-4834-A15D-A305BEA8C58CQ39320921-C3858EA8-A70D-4EAD-8942-7C007A3B10D5
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Influenza vaccines: present and future.
@ast
Influenza vaccines: present and future.
@en
Influenza vaccines: present and future.
@nl
type
label
Influenza vaccines: present and future.
@ast
Influenza vaccines: present and future.
@en
Influenza vaccines: present and future.
@nl
prefLabel
Influenza vaccines: present and future.
@ast
Influenza vaccines: present and future.
@en
Influenza vaccines: present and future.
@nl
P2860
P356
P1476
Influenza vaccines: present and future.
@en
P2093
Adolfo García-Sastre
P2860
P356
10.1172/JCI0215999
P407
P50
P577
2002-07-01T00:00:00Z